Published Date：Jan. 2021
Industry：
Pages：113 Table Number：133
Single User Price：￥3650.00
Enterprise User Price：￥5600.00
Summary As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%. Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States. In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter. Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970. Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Rare Disease Treatment market in this environment. In terms of revenue, this research report indicated that the global Rare Disease Treatment market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Rare Disease Treatment industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments. The Novartis aims at producing XX Rare Disease Treatment in 2020, with XX % production to take place in global market, Pfizer accounts for a volume share of XX %. Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Rare Disease Treatment Market by XYZResearch Include China EU USA Japan India Southeast Asia South America Competitive Analysis; Who are the Major Players in Rare Disease Treatment Market? Novartis Pfizer F. Hoffmann-La Roche Celgene AbbVie Johnson and Johnson Shire Alexion Novo Nordisk Sanofi Bayer Amgen Allergan Eisai Bristol-Myers Squibb Merck Vertex Pharmaceuticals Baxter BioMarin Teva Pharmaceutical Industries ... Major Type of Rare Disease Treatment Covered in XYZResearch report: Originator Drugs Generic Drugs Application Segments Covered in XYZResearch Market Hospital Pharmacies Specialty Pharmacies Retail Pharmacies For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents Global Rare Disease Treatment Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate 1 Market Scope 1.1 Product Details and Introduction 1.1.1 Originator Drugs -Product Introduction and Major Manufacturers 1.1.2 Generic Drugs -Product Introduction and Major Manufacturers 1.2 Market Snapshot 1.2.1 Major Companies Overview 1.2.2 Market Concentration 1.2.3 Six-Year Compound Annual Growth Rate (CAGR) 2 Global Rare Disease Treatment Market Assessment, by Segmentation 2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026) 2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026) 2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026) 3 Regional Market Analysis 3.1 China Rare Disease Treatment Market 3.1.1 Top Companies leading Rare Disease Treatment Development in China (2015-2020) 3.1.2 Sales Value of Major Company in China Market (2015-2020) 3.1.3 China Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) 3.1.4 Sales in China Market, by Type (2015-2026) 3.2 EU Rare Disease Treatment Market 3.2.1 Top Companies leading Rare Disease Treatment Development in EU (2015-2020) 3.2.2 Sales Value of Major Company in EU Market (2015-2020) 3.2.3 EU Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) 3.2.4 Sales in EU Market, by Type (2015-2026) 3.3 USA Rare Disease Treatment Market 3.3.1 Top Companies leading Rare Disease Treatment Development in USA (2015-2020) 3.3.2 Sales Value of Major Company in USA Market (2015-2020) 3.3.3 USA Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) 3.3.4 Sales in USA Market, by Type (2015-2026) 3.4 Japan Rare Disease Treatment Market 3.4.1 Top Companies leading Rare Disease Treatment Development in Japan (2015-2020) 3.4.2 Sales Value of Major Company in Japan Market (2015-2020) 3.4.3 Japan Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) 3.4.4 Sales in Japan Market, by Type (2015-2026) 3.5 India Rare Disease Treatment Market 3.5.1 Top Companies leading Rare Disease Treatment Development in India (2015-2020) 3.5.2 Sales Value of Major Company in India Market (2015-2020) 3.5.3 India Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) 3.5.4 Sales in India Market, by Type (2015-2026) 3.6 Southeast Asia Rare Disease Treatment Market 3.6.1 Top Companies leading Rare Disease Treatment Development in Southeast Asia (2015-2020) 3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020) 3.6.3 Southeast Asia Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) 3.6.4 Sales in Southeast Asia Market, by Type (2015-2026) 3.7 South America Rare Disease Treatment Market 3.7.1 Top Companies leading Rare Disease Treatment Development in South America (2015-2020) 3.7.2 Sales Value of Major Company in South America Market (2015-2020) 3.7.3 South America Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) 3.7.4 Sales in South America Market, by Type (2015-2026) 4 Value Chain (Impact of COVID-19) 4.1 Rare Disease Treatment Value Chain Analysis 4.1.1 Upstream 4.1.2 Downstream 4.2 COVID-19 Impact on Rare Disease Treatment Industry 4.2.1 Industrial Policy Issued Under the Epidemic Situation 4.3 Cost-Under the Epidemic Situation 4.3.1 Cost of Raw Material 4.4 Channel Analysis 4.4.1 Distribution Channel-Under the Epidemic Situation 4.4.2 Distributors 5 Regional Market Forecast (2021-2026) 5.1 Global Rare Disease Treatment Sales and Growth Rate (2021-2026) 5.2 Global Rare Disease Treatment Sales Value and Growth Rate (2021-2026) 6 Rare Disease Treatment Competitive Analysis 6.1 Novartis 6.1.1 Novartis Company Profiles 6.1.2 Novartis Product Introduction 6.1.3 Novartis Rare Disease Treatment Production, Revenue (2015-2020) 6.1.4 SWOT Analysis 6.2 Pfizer 6.2.1 Pfizer Company Profiles 6.2.2 Pfizer Product Introduction 6.2.3 Pfizer Rare Disease Treatment Production, Revenue (2015-2020) 6.2.4 SWOT Analysis 6.3 F. Hoffmann-La Roche 6.3.1 F. Hoffmann-La Roche Company Profiles 6.3.2 F. Hoffmann-La Roche Product Introduction 6.3.3 F. Hoffmann-La Roche Rare Disease Treatment Production, Revenue (2015-2020) 6.3.4 SWOT Analysis 6.4 Celgene 6.4.1 Celgene Company Profiles 6.4.2 Celgene Product Introduction 6.4.3 Celgene Rare Disease Treatment Production, Revenue (2015-2020) 6.4.4 SWOT Analysis 6.5 AbbVie 6.5.1 AbbVie Company Profiles 6.5.2 AbbVie Product Introduction 6.5.3 AbbVie Rare Disease Treatment Production, Revenue (2015-2020) 6.5.4 SWOT Analysis 6.6 Johnson and Johnson 6.6.1 Johnson and Johnson Company Profiles 6.6.2 Johnson and Johnson Product Introduction 6.6.3 Johnson and Johnson Rare Disease Treatment Production, Revenue (2015-2020) 6.6.4 SWOT Analysis 6.7 Shire 6.7.1 Shire Company Profiles 6.7.2 Shire Product Introduction 6.7.3 Shire Rare Disease Treatment Production, Revenue (2015-2020) 6.7.4 SWOT Analysis 6.8 Alexion 6.8.1 Alexion Company Profiles 6.8.2 Alexion Product Introduction 6.8.3 Alexion Rare Disease Treatment Production, Revenue (2015-2020) 6.8.4 SWOT Analysis 6.9 Novo Nordisk 6.9.1 Novo Nordisk Company Profiles 6.9.2 Novo Nordisk Product Introduction 6.9.3 Novo Nordisk Rare Disease Treatment Production, Revenue (2015-2020) 6.9.4 SWOT Analysis 6.10 Sanofi 6.10.1 Sanofi Company Profiles 6.10.2 Sanofi Product Introduction 6.10.3 Sanofi Rare Disease Treatment Production, Revenue (2015-2020) 6.10.4 SWOT Analysis 6.11 Bayer 6.12 Amgen 6.13 Allergan 6.14 Eisai 6.15 Bristol-Myers Squibb 6.16 Merck 6.17 Vertex Pharmaceuticals 6.18 Baxter 6.19 BioMarin 6.20 Teva Pharmaceutical Industries 7 Conclusion
List of Tables and Figures Figure Product Introduction Table Production (K Units) and Revenue (Million USD) of Major Players (2015-2020) Figure Global Rare Disease Treatment Production Market Share of Top 5 Players Table CAGR of Major Market (2021-2026) Table CAGR in Terms of Production of Each Type (2015-2026) Table CAGR in Terms of Production of Each Application (2015-2026) Table Global Rare Disease Treatment Sales (K Unit) by Type (2015-2026) Figure Global Rare Disease Treatment Sales (K Unit) and Growth Rate (2015-2026) Figure Global Rare Disease Treatment Sales Market Share (%) by Type (2019 -2020) Table Global Rare Disease Treatment Sales Value (Million USD) by Type (2015-2026) Figure Global Rare Disease Treatment Sales Value (Million USD) and Growth Rate (2015-2026) Figure Global Rare Disease Treatment Sales Value Market Share (%) by Type (2019-2020) Table Global Rare Disease Treatment Sales (K Unit) by Application (2015-2026) Table China Rare Disease Treatment Sales (K Unit) of Major Company (2015-2020) Table China Rare Disease Treatment Sales Market Share of Major Company (2015-2020) Table China Rare Disease Treatment Sales Value (Million USD) of Major Company (2015-2020) Figure China Rare Disease Treatment Sales Value (Million USD) and Growth Rate (2015-2020) Table China Rare Disease Treatment Sales Value Share of Major Company (2015-2020) Table China Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) Table China Rare Disease Treatment Sales (Unit) by Type (2015-2026) Figure China Rare Disease Treatment Sales (Unit) by Type (2015-2026) Table EU Rare Disease Treatment Sales (K Unit) of Major Company (2015-2020) Table EU Rare Disease Treatment Sales Market Share of Major Company (2015-2020) Table EU Rare Disease Treatment Sales Value (Million USD) of Major Company (2015-2020) Figure EU Rare Disease Treatment Sales Value (Million USD) and Growth Rate (2015-2020) Table EU Rare Disease Treatment Sales Value Share of Major Company (2015-2020) Table EU Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) Table EU Rare Disease Treatment Sales (Unit) by Type (2015-2026) Figure EU Rare Disease Treatment Sales (Unit) by Type (2015-2026) Table USA Rare Disease Treatment Sales (K Unit) of Major Company (2015-2020) Table USA Rare Disease Treatment Sales Market Share of Major Company (2015-2020) Table USA Rare Disease Treatment Sales Value (Million USD) of Major Company (2015-2020) Figure USA Rare Disease Treatment Sales Value (Million USD) and Growth Rate (2015-2020) Table USA Rare Disease Treatment Sales Value Share of Major Company (2015-2020) Table USA Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) Table USA Rare Disease Treatment Sales (Unit) by Type (2015-2026) Figure USA Rare Disease Treatment Sales (Unit) by Type (2015-2026) Table Japan Rare Disease Treatment Sales (K Unit) of Major Company (2015-2020) Table Japan Rare Disease Treatment Sales Market Share of Major Company (2015-2020) Table Japan Rare Disease Treatment Sales Value (Million USD) of Major Company (2015-2020) Figure Japan Rare Disease Treatment Sales Value (Million USD) and Growth Rate (2015-2020) Table Japan Rare Disease Treatment Sales Value Share of Major Company (2015-2020) Table Japan Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) Table Japan Rare Disease Treatment Sales (Unit) by Type (2015-2026) Figure Japan Rare Disease Treatment Sales (Unit) by Type (2015-2026) Table India Rare Disease Treatment Sales (K Unit) of Major Company (2015-2020) Table India Rare Disease Treatment Sales Market Share of Major Company (2015-2020) Table India Rare Disease Treatment Sales Value (Million USD) of Major Company (2015-2020) Figure India Rare Disease Treatment Sales Value (Million USD) and Growth Rate (2015-2020) Table India Rare Disease Treatment Sales Value Share of Major Company (2015-2020) Table India Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) Table India Rare Disease Treatment Sales (Unit) by Type (2015-2026) Figure India Rare Disease Treatment Sales (Unit) by Type (2015-2026) Table Southeast Asia Rare Disease Treatment Sales (K Unit) of Major Company (2015-2020) Table Southeast Asia Rare Disease Treatment Sales Market Share of Major Company (2015-2020) Table Southeast Asia Rare Disease Treatment Sales Value (Million USD) of Major Company (2015-2020) Figure Southeast Asia Rare Disease Treatment Sales Value (Million USD) and Growth Rate (2015-2020) Table Southeast Asia Rare Disease Treatment Sales Value Share of Major Company (2015-2020) Table Southeast Asia Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) Table Southeast Asia Rare Disease Treatment Sales (Unit) by Type (2015-2026) Figure Southeast Asia Rare Disease Treatment Sales (Unit) by Type (2015-2026) Table South America Rare Disease Treatment Sales (K Unit) of Major Company (2015-2020) Table South America Rare Disease Treatment Sales Market Share of Major Company (2015-2020) Table South America Rare Disease Treatment Sales Value (Million USD) of Major Company (2015-2020) Figure South America Rare Disease Treatment Sales Value (Million USD) and Growth Rate (2015-2020) Table South America Rare Disease Treatment Sales Value Share of Major Company (2015-2020) Table South America Rare Disease Treatment Price (USD/Unit), by Type (2019-2020) Table South America Rare Disease Treatment Sales (Unit) by Type (2015-2026) Figure South America Rare Disease Treatment Sales (Unit) by Type (2015-2026) Figure Value Chain Structure of Rare Disease Treatment Table Value Chain Table Key Suppliers of Raw Material/Components Table Key Downstream Customer in Each Application Field Table Industry News List of Rare Disease Treatment Figure Cost Structure of Rare Disease Treatment in 2020 Table Distributors/Traders List Table Regional Market Sales (K Unit) (2021-2026) Table Regional Market Sales Share (2021-2026) Figure Global Rare Disease Treatment Sales (Unit), Growth Rate & Market Share (2021-2026) Table Regional Market Sales Value (Million USD) (2021-2026) Table Regional Market Sales Value Share (2021-2026) Figure Global Rare Disease Treatment Sales Value (Million USD), Growth Rate & Market Share (2021-2026) Table Novartis Profiles Table Novartis Rare Disease Treatment Product Introduction Table Novartis Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Novartis SWOT Analysis Table Pfizer Profiles Table Pfizer Rare Disease Treatment Product Introduction Table Pfizer Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Pfizer SWOT Analysis Table F. Hoffmann-La Roche Profiles Table F. Hoffmann-La Roche Rare Disease Treatment Product Introduction Table F. Hoffmann-La Roche Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure F. Hoffmann-La Roche SWOT Analysis Table Celgene Profiles Table Celgene Rare Disease Treatment Product Introduction Table Celgene Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Celgene SWOT Analysis Table AbbVie Profiles Table AbbVie Rare Disease Treatment Product Introduction Table AbbVie Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure AbbVie SWOT Analysis Table Johnson and Johnson Profiles Table Johnson and Johnson Rare Disease Treatment Product Introduction Table Johnson and Johnson Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Johnson and Johnson SWOT Analysis Table Shire Profiles Table Shire Rare Disease Treatment Product Introduction Table Shire Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Shire SWOT Analysis Table Alexion Profiles Table Alexion Rare Disease Treatment Product Introduction Table Alexion Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Alexion SWOT Analysis Table Novo Nordisk Profiles Table Novo Nordisk Rare Disease Treatment Product Introduction Table Novo Nordisk Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Novo Nordisk SWOT Analysis Table Sanofi Profiles Table Sanofi Rare Disease Treatment Product Introduction Table Sanofi Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Sanofi SWOT Analysis Table Bayer Profiles Table Bayer Rare Disease Treatment Product Introduction Table Bayer Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Bayer SWOT Analysis Table Amgen Profiles Table Amgen Rare Disease Treatment Product Introduction Table Amgen Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Amgen SWOT Analysis Table Allergan Profiles Table Allergan Rare Disease Treatment Product Introduction Table Allergan Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Allergan SWOT Analysis Table Eisai Profiles Table Eisai Rare Disease Treatment Product Introduction Table Eisai Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Eisai SWOT Analysis Table Bristol-Myers Squibb Profiles Table Bristol-Myers Squibb Rare Disease Treatment Product Introduction Table Bristol-Myers Squibb Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Bristol-Myers Squibb SWOT Analysis Table Merck Profiles Table Merck Rare Disease Treatment Product Introduction Table Merck Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Merck SWOT Analysis Table Vertex Pharmaceuticals Profiles Table Vertex Pharmaceuticals Rare Disease Treatment Product Introduction Table Vertex Pharmaceuticals Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Vertex Pharmaceuticals SWOT Analysis Table Baxter Profiles Table Baxter Rare Disease Treatment Product Introduction Table Baxter Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure Baxter SWOT Analysis Table BioMarin Profiles Table BioMarin Rare Disease Treatment Product Introduction Table BioMarin Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020) Figure BioMarin SWOT Analysis Table Teva Pharmaceutical Industries Profiles Table Teva Pharmaceutical Industries Rare Disease Treatment Product Introduction Table Teva Pharmaceutical Industries Rare Disease Treatment Sales (Unit), Sales Value (Million USD), Price (USD/Unit) and Gross Profit (2015-2020)
